Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741554 | 0.87 | SLC6A4 (0.52) | SLC6A2SLC6A4OPRM1SLC22A1OPRD1 | |
| SCHEMBL6743000 | 0.85 | SLC6A4 (0.50) | SLC6A2SLC6A4OPRM1SLC22A1OPRD1 | |
| SCHEMBL4374880 | 0.85 | SLC6A2 (0.66) | SLC6A2SLC6A4OPRM1SLC22A1OPRD1 | |
| SCHEMBL6742994 | 0.84 | SLC6A2 (0.52) | SLC6A2SLC6A4OPRM1SLC22A1OPRD1 | |
| SCHEMBL6744430 | 0.83 | SLC6A4 (0.48) | SLC6A2SLC6A4OPRM1SLC22A1OPRD1 | |
| SCHEMBL6743948 | 0.83 | SLC6A4 (0.52) | SLC6A2SLC6A4OPRM1SLC22A1OPRD1 | |
| SCHEMBL18982844 | 0.82 | SLC6A2 (0.72) | SLC6A2SLC6A4OPRM1SLC22A1OPRD1 | |
| SCHEMBL7172155 | 0.82 | SLC6A4 (0.60) | SLC6A2SLC6A4OPRM1SLC22A1OPRD1 | |
| SCHEMBL6741500 | 0.82 | SLC6A4 (0.54) | SLC6A2SLC6A4OPRM1SLC22A1OPRD1 | |
| SCHEMBL6784987 | 0.81 | OPRM1 (0.64) | SLC6A2SLC6A4OPRM1SLC22A1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828345-B2 | Tertiary amines such as 2-dimethylaminomethyl-1-(3-methoxy-phenyl)-6-methylcyclohexanol, used as analgesics | GRUENENTHAL GMBH (DE) | 2004-12-07 | — | — | US | disclosed |
| US-20030220389-A1 | O-substituted 6-methyltramadol derivatives | GRUENENTHAL GMBH (DE) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220389-A1 | O-substituted 6-methyltramadol derivatives | OPRK1, TPMT, OPRM1 | SLC6A2 127/4885SLC6A4 65/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.